Introduction
At present, various treatment methods are applied for patients with gastric cancer, including endoscopic treatment, open surgery, laparoscopic surgery, and neoadjuvant chemotherapy. Thus, an accurate preoperative diagnosis of regional lymph node metastases in gastric cancer is essential in deciding upon a treatment strategy. The guidelines for gastric cancer treatment published by the Japanese Gastric Cancer Association (JGCA) in both the fi rst edition (2001) [1] and the second edition (2004) [2] recommend the mode of treatment based on the tumor stage according to evidencebased fi ndings. Endoscopic treatment, like endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), is recommended for lymph nodenegative patients, and partial and laparoscopic gastrectomy with limited extent lymph node dissection is recommended for patients who are possibly nodepositive. In patients with locally advanced cancer, neoadjuvant chemotherapy may sometimes be recommended for node-positive patients. Most recent clinical trials have demonstrated that paraaortic lymph node dissection does not lead to any survival benefi t compared with the standard regional dissection, D2 [3] . Thus, precise lymph-node staging greatly infl uences the decision on the mode of treatment. For the evaluation of regional lymph nodes in gastric cancer, the nodes have generally been defi ned according to size or morphologic criteria in several imaging modalities, such as computed tomography (CT), endoscopic ultrasonography (EUS), and conventional magnetic resonance imaging (MRI), but these methods have not been confi rmed as suffi ciently effective [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Recently, the use of ultrasmall superparamagnetic iron oxide (USPIO), which is a lympho-graphic contrast medium for MR imaging, has been of interest in the evaluation of lymph nodes in patients with neck, prostatic, rectal, esophageal, breast, and gastric cancers [14] [15] [16] [17] [18] [19] [20] .
We previously reported on the effi cacy of MRI examination using USPIO with a comparison of preand post-contrast T2*-weighted images in patients with gastric cancer, wherein the results demonstrated a diagnostic performance superior to those obtained by other diagnostic methods [20] . However, the following three problems arose in this examination: (1) the detectability of perigastric lymph nodes in reference to CT images was very low (9.7%); (2) the performance of a comparison of T2*-weighted images before and after administration of USPIO could affect patient compliance; and (3) the positive predictive value for T2*-weighted images was relatively low, 85.5%.
Accordingly, we carried out the present study to demonstrate the superiority of the introduction of T1-,T2-, and T2*-weighted images following the administration of USPIO, rather than the use of T2*-weighted images before and after administration of USPIO (as reported in our previous work [20] ), in the detection and accurate diagnosis of lymph node status in patients with gastric cancer.
Patients, materials, and methods

Patients
From June 2005 to June 2007, 31 patients (29 men and 2 women, ages ranging from 51 to 84 years; mean age, 67.8 years) were enrolled in the study. All patients were diagnosed with gastric cancer histologically via gastroendoscopy and were scheduled for surgery. All patients underwent primary tumor resection and regional lymph node dissection. This study protocol was approved by the ethics committee at Osaka Medical College. Written informed consent was obtained from all patients prior to the study. Of the 31 patients, 20 patients underwent distal gastrectomy, 1 patient underwent proximal gastrectomy, and 10 patients underwent total gastrectomy together with regional lymph node dissection. The definition of the anatomical locations of the regional lymph nodes was based on the Japanese classifi cation of gastric carcinoma (JCGC) [21] .
Contrast agent
Ultrasmall superparamagnetic iron oxide (USPIO; Ferumoxtran-10; Combidex; Advanced Magnetics, Boston, MA, USA) was reconstituted and diluted in 100 ml of 0.9% normal saline, and administered intravenously through a 5.0-µm microfi lter by drip infusion for 60 min, at a dose of 2.6 mg of iron per kilogram of body weight. This dose was chosen on the basis of a phase II dose-ranging study and phase III results [22, 23] . Adverse events were recorded from the time of administration of USPIO to surgery. In the 31 patients, no subjective or objective adverse events of any kind were experienced.
MR imaging techniques
Patients were scanned using a 1.5-T MRI scanner (SIGNA Horizon EchoSpeed LX 1.5TCV/I; General Electric Medical Systems, Milwaukee, WI, USA) in the supine position. Before MRI examination, patients were fasted for 3 h. Glucagon (1 mg; Glucagon G Novo; Novonordisk, Tokyo, Japan) was administered intramuscularly approximately 5 min before the MRI examination unless it was contraindicated for the patient's condition.
Twenty-four hours after the administration of USPIO, T1-weighted, T2-weighted, and T2*-weighted MR images were obtained. The parameters for the T1- 
Image analysis
Before surgery, all images were analyzed independently by one radiologist (M. M.) and one surgeon (T. T.) who were well trained in MRI. In cases of discrepancy between the two readers, a consensus was reached through discussion. We detected regional lymph nodes on post-contrast T1-and T2-weighted images.
(1) We evaluated lymph nodes on post-contrast T2*-weighted images and diagnosed lymph nodes using the following previously reported criteria: a node with pattern A having an overall low signal intensity due to diffuse uptake of USPIO was diagnosed as nonmetastatic; while a node with pattern B having a partial high signal intensity due to partial uptake of USPIO, or a node with pattern C having an overall high signal intensity due to no uptake of USPIO, was diagnosed as metastatic ( Fig. 1 ). (2) We evaluated lymph nodes on both post-contrast T2*-and T1-weighted images. Here, we subdivided the nodes with pattern B, referring to T1-weighted images as follows: a node for which the highintensity area on T2*-weighted images was not defi ned as adipose tissue on T1-weighted images (pattern B1) was metastatic ( Fig. 2) , while a node for which the high-intensity area was defi ned as adipose tissue (pattern B2) was nonmetastatic (Fig. 3) .
Histopathological evaluation
To achieve the most precise correlation between MRI lymph node imagings and histopathological fi ndings, histopathological examination was performed in lymph nodes 5 mm or more in size [20] . The surgeons operated with no information on the MRI images. The dissected lymph nodes were fi xed in formalin for at least 24 h. The largest cut surface of each lymph node was sectioned and stained with hematoxylin and eosin. A pathologist (Y. K.) diagnosed each lymph node as metastatic or nonmetastatic. One surgeon (T. T.) and one pathologist (Y. K.) performed a node-to-node correlation between the post-contrast MRI and histopathological fi ndings.
Statistical analysis
We calculated sensitivity, specifi city, positive and negative predictive values, and overall accuracy based on the lymph nodes using the diagnostic criteria that refer to patterns A, B, and C and patterns A, B1, B2, and C, individually in the total node region, in the perigastric node region, in the retroperitoneal lymph node region, and in the paraaortic lymph node region.
Results
( [24] . In terms of tumor histology, 14 tumors were tubular adenocarcinomas (well-differentiated type), 5 were tubular adenocarcinomas (moderately differentiated type), 5 were solid-type poorly differentiated adeno carcinomas, 6 were nonsolid-type poorly differentiated adenocarcinomas, and 1 was a mucinous adenocarcinoma. (2) A total of 1000 lymph nodes from the 31 patients, including 184 histologically proven metastatic lymph nodes, were dissected during surgery. As (Table 3) . Based on the new diagnostic criteria, the results exhibited 96.2% sensitivity, 98.3% specifi city, 90.1% PPV, 99.0% NPV, and 97.1% accuracy ( Table 2) . (5) In the 311 perigastric nodes identifi ed with postcontrast MRI, the results exhibited 100% sensitivity, 97.4% specifi city, 93.0% PPV, 100% NPV, and 98.1% accuracy using the new diagnostic criteria.
(6) In the 198 retroperitoneal nodes identifi ed with post-contrast MRI, the results exhibited 83.3% sensitivity, 97.1% specifi city, 80.0% PPV, 98.1% NPV, and 95.5% accuracy with the new diagnostic criteria. The reason that the results for retroperitoneal lymph nodes were worse than those for other locations is unclear, but may be related to an insuffi cient number being tested. (7) In the ten paraaortic nodes identifi ed with postcontrast MRI, the results exhibited 100% specifi city, 100% NPV, and 100% accuracy with the new diagnostic criteria. According to these results, it seems that this new method for evaluating lymph node status may have the potential to correctly identify the subgroup of patients for whom palliative treatment is indicated or patients who would need D3 lymphadenectomy.
Discussion
It has been reported that lymph node metastasis is an important prognostic factor in gastric cancer [25, 26] . And so the treatment strategies for gastric cancer are diverse as to N-staging, including endoscopic treatment, laparoscopic surgery, open surgery, and neoadjuvant chemotherapy, as indicated in the guidelines for gastric cancer treatment [1, 2] . Endoscopic treatment can be performed for some intramucosal and submucosal cancers with no lymph node metastases [27] . However, laparoscopic surgery cannot be used for patients with retroperitoneal lymph node metastases [28] . The utility of neoadjuvant chemotherapy has recently been discussed for some patients with advanced gastric cancer with suspected extensive lymph node metastases [29, 30] . Therefore, preoperative assessment of regional lymph node involvement in gastric cancer is essential in deciding upon a treatment strategy. In the evaluation of regional lymph nodes in gastric cancer, various imaging modalities, such as computed tomography (CT), endoscopic ultrasonography (EUS), and conventional magnetic resonance imaging (MRI) have been used, with lymph nodes assessed according to size or morphologic criteria. The reported accuracy of CT, EUS, and conventional MRI for the N-staging of gastric cancer was 43%-80%, 65%-87%, and 34%-65%, respectively, and this level of diagnostic perfor- mance was not suffi cient for making a decision among treatment strategies for gastric cancer [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Recently, a lymphographic contrast medium of iron-containing nanoparticles, referred to as ultrasmall superparamagnetic iron oxide (USPIO), has received attention in the evaluation of lymph nodes in various types of malignancy, such as neck, prostatic, rectal esophageal, breast, and gastric cancers [14] [15] [16] [17] [18] [19] [20] . After the intravenous injection of USPIO, the nanoparticles circulate systemically and accumulate in the interstitium. These nanoparticles in the interstitium are internalized by macrophages and are drained through lymphatic vessels to the lymph nodes. The iron-containing nanoparticles accumulate in normal lymph nodes, which enhances susceptibility effects and reduces the nodal T2* signal. In contrast, because metastatic lymph nodes lack reticuloendothelial activity, they are unable to take up the iron-containing nanoparticles that cause local fi eld heterogeneity [22] . We have previously reported on the effi cacy of MRI examination using USPIO in the evaluation of lymph nodes in patients with gastric cancer, wherein the results demonstrated that the sensitivity, specifi city, PPV, NPV and accuracy were 100%, 92.6%, 85.5%, 100%, and 94.8%, respectively. These parameters were far superior to those achieved previously with evaluations using other diagnostic methods such as CT, US, and conventional MRI. However, there were several problems, as follows.
(1) In our previous study, lymph nodes were identifi ed on pre-and post-contrast T2*-weighted images in reference to CT images, and the detectability of perigastric lymph nodes was relatively low (9.7%). The diffi culty in the detection of lymph nodes by this technique was considered to be due to the fact that the morphology and degree of distension of the stomach changed between the pre-and post-contrast T2*-weighted images, and this occurred likewise for the CT images, which were performed on different days. Harisinghani et al. [31] emphasized that, in comparison to T2*-weighted images, T1-and T2-weighted images were more suitable for the identifi cation of lymph nodes because of the high spatial resolution. Therefore, we selected the method in which we detected lymph nodes on postcontrast T1-and T2-weighted images and evaluated them on post-contrast T2*-weighted images. As a result, the detectability of perigastric lymph nodes increased to 47.0%. (2) It was reported that there was no signifi cant difference in diagnostic performance between a combined study of pre-and post-contrast images and a post-contrast study alone [19, 31] . Therefore, we tried, in this present study, to examine the postcontrast study alone, and compared the results to those from our previous study. The diagnostic performance in the post-contrast study alone gave sensitivity, specifi city, and accuracy of 96.2%, 92.5%, and 93.3%, respectively, values which were rather similar to those from our previous study, where the sensitivity, specifi city, and accuracy were 100%, 92.6%, and 94.8%, respectively. (3) Recently, it was reported that a partial high signal in the lymph nodes on post-contrast T2*-weighted images could refl ect tumor replacement or adipose tissue in the lymphatic hilum, and, therefore, careful scrutiny of T1-weighted images was required to identify a fatty central hilum [18] . We then utilized the new diagnostic criteria with subdivision of the pattern B nodes referring to T1-weighted images as follows: nodes with a high intensity area on T2*-weighted images, which was not defi ned as adipose tissue on the T1-weighted images (pattern B1), were diagnosed as metastatic. At the same time, the nodes with a high intensity area on the T2*-weighted images, which was defi ned as adipose tissue on T1-weighted images (pattern B2), were diagnosed as nonmetastatic. As a result, the diagnostic performance with the new diagnostic criteria gave specifi city and accuracy of 98.3%, and 97.1%, respectively, values which were superior to those from our previous study [20] , where specifi city and accuracy were 92.6%, and 94.8%, respectively.
Conclusion
The present study indicates that the assessment of lymph node metastases on USPIO-post-contrast MRI alone using the new diagnostic criteria was useful in the diagnosis of regional lymph node metastases in gastric cancer. This diagnostic performance can contribute to making better decisions on the appropriate treatment strategy in patients with gastric cancer.
